Sign in
Taking peoplePhase 1

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Key facts

Who runs it
Shanghai Jiaolian Drug Research and Development Co., Ltd
Where
China5 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
52 people, planned
Started
2 Mar 2023
Expected to end
30 Dec 2027
Type of study
Interventional, 3 groups
Treatments tested
  • B007
Record updated
30 April 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Subjects who have fully understood this study and voluntarily signed the informed consent form
  • Male or female subjects, aged between 18 and 75 years
  • Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy
  • Subjects with systolic blood pressure ≤ 140 mmHg and diastolic blood pressure ≤ 90 mmHg at screening
  • If taking ACEI(Angiotensin converting enzyme inhibitors), ARB(Angiotensin receptor blocker), a stable dose within 4 weeks before screening is required
  • Subjects who are able to follow the study protocol as judged by the investigator

Who cannot take part

  • Subjects with uncontrolled blood pressure as judged by the investigator within 3 months before screening
  • Subjects with decreases in urine protein ≥ 50% within 6 months before screening
  • Subjects who have received or are receiving renal replacement therapy
  • Subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment
  • Subjects who received live vaccination, major surgery, or participated in other clinical trials within 28 days before receiving the study drug
  • Pregnant or lactating women; women of childbearing potential who have not been sterilized do not agree to use appropriate contraceptive measures during treatment and for at least 12 months after the last dose of the study drug
  • Subjects with type 1 diabetes mellitus, or those with type 2 diabetes mellitus who are diagnosed as diabetic nephropathy by percutaneous renal biopsy
  • Subjects with active bacterial, viral, fungal, mycobacterial, parasitic or other infections requiring systemic antibiotics or antiviral therapy
  • Subjects with known history of severe allergic reactions to humanized monoclonal antibodies;
  • Subjects with serious, progressive, or uncontrolled disease that may increase risks during the participation in the study as assessed by the investigator
  • Subjects with a history of alcoholism or drug abuse within 12 months
  • Subjects with positive hepatitis B surface antigen; those with positive hepatitis C virus antibody; those with a history of immunodeficiency
  • Other conditions unsuitable for participation in this study determined by the Investigator
  • Subjects with CD4+ T lymphocyte count < 300 cells/μL
  • Subjects with secondary membranous nephropathy

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy

The 3 groups in the trial

  • B007:350mgTreatment being tested

    B007:350mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

    Treatment: B007

  • B007:700mgTreatment being tested

    B007: 700mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

    Treatment: B007

  • B007:1000mgTreatment being tested

    B007: 1000mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

    Treatment: B007

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy
Criteria questions
Built from NCT05668403, who can take part
Record updated
30 April 2026